title: [Anti-tumor activity of folate receptor targeting docetaxel-loaded membrane-modified liposomes].
abstract: The anti-tumor activity of folate receptor targeting docetaxel-loaded membrane-modified liposomes (FA-PDCT-L) was investigated in vitro and in vivo. FA-PDCT-L was prepared by organic solvent injection method. Transmission electron microscope, dynamic light scattering and electrophoretic light scattering were employed to study the physicochemical parameters of FA-PDCT-L. The inhibitory effects of docetaxel injection (DCT-I), non-modified DCT liposomes (DCT-L) and FA-PDCT-L on the growth of MCF-7 and A-549 cells at different incubation times were detected by CCK-8 assay; and the hemolytic test was employed in vitro. Tumor mice were randomized into 4 groups: DCT-I, DCT-L, FA-PDCT-L and control group (normal saline), and given drugs at 10 mg x kg(-1) x d(-1) through tail vein. The tumor volume, mice weight, inhibition rate of tumor and life span were measured at the end of experiments. The IC50 of the FA-PDCT-L for MCF-7 and A549 cell lines were significantly lower than that of DCT-I and DCT-L, without hemolysis reaction observed. Compared with control group, the weights of tumor in DCT-I, DCT-L and FA-PDCT-L were decreased, especially for FA-PDCT-L, with inhibitory rates at 79.03 % (P < 0.05). The life span and median survival time of FA-PDCT-L treated mice were significantly higher than that of DCT-I and DCT-L. In conclusion, FA-PDCT-L shows a good anti-tumor activity, indicating that it is potential carriers for DCT in the treatment of tumor.
authors.affiliation: National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi University of Traditional Chinese Medicine, Nanchang 330006, China.
authors.forename: Xiang
authors.initials: X
authors.lastname: Li
authors.forename: Jing
authors.initials: J
authors.lastname: Zhang
authors.forename: Dong-Kai
authors.initials: DK
authors.lastname: Wang
authors.forename: Wei-San
authors.initials: WS
authors.lastname: Pan
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D003487:Cyanoacrylates / Q000737:chemistry; D000077143:Docetaxel; D004337:Drug Carriers; D005260:Female; D058973:Folate Receptors, GPI-Anchored / Q000737:chemistry*; D006801:Humans; D020128:Inhibitory Concentration 50; D008081:Liposomes / Q000737:chemistry; D008175:Lung Neoplasms / Q000473:pathology; D061986:MCF-7 Cells; D051379:Mice; D009368:Neoplasm Transplantation; D010316:Particle Size; D011092:Polyethylene Glycols / Q000737:chemistry; D011817:Rabbits; D011897:Random Allocation; D012510:Sarcoma 180 / Q000473:pathology; D043823:Taxoids / Q000008:administration & dosage / Q000494:pharmacology; D047368:Tumor Burden / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D003487:Cyanoacrylates; D004337:Drug Carriers; D058973:Folate Receptors, GPI-Anchored; D008081:Liposomes; D043823:Taxoids; D000077143:Docetaxel; D011092:Polyethylene Glycols